3,110 件 ・ 関連度順
概要と使いどころ
Manages project versioning following Semantic Versioning (SemVer) principles. Calculates increments based on changes and synchronizes version across documentation and metadata. Use when the user asks to "bump the version", "prepare a release", or when the `changelog` skill calls for a release.
日本語の概要は準備中です。原文の説明を表示しています。
Standardizes git operations, branch management, and disaster recovery. Use when committing, branching, or resolving conflicts. For commit formatting, see conventional-commits.
日本語の概要は準備中です。原文の説明を表示しています。
Generates and maintains changelogs following Keep a Changelog format. Use when updating release notes, finishing tasks, or tagging versions. For version bumps, see semantic-versioning.
日本語の概要は準備中です。原文の説明を表示しています。
Intelligent README.md generation prompt that analyzes project documentation structure and creates comprehensive repository documentation. Scans ./ directory files and creates a README.md file for the project. Only used when creating a new repository. or when the README.md file is missing.
日本語の概要は準備中です。原文の説明を表示しています。
Structured competitor teardown skill. Use when scraping competitor sites, extracting pricing/features/positioning, or analyzing strategic gaps. For general research, see market-research.
日本語の概要は準備中です。原文の説明を表示しています。
Structured validation framework that scores product ideas. Use when evaluating problem severity, willingness-to-pay, or founder-market fit. For market intelligence, see market-research.
日本語の概要は準備中です。原文の説明を表示しています。
Meta-skill that generates compliant PLAYBOOK.md files following the BRAINIAC template. Use when creating or editing modules in the command center. For general readme creation, see create-readme.
日本語の概要は準備中です。原文の説明を表示しています。
Deep web research skill using Firecrawl MCP. Use when estimating market size (TAM/SAM/SOM), analyzing trends, or scraping competitors. For competitor teardowns, see competitor-analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Busabase-backed App-in-Skill control-panel/workspace for a deal analyst to model revenue-based-financing (RBF) deals for SME businesses (retail/F&B chain stores). Use when the user invokes $kelly-revshare-simulator or /kelly-revshare-simulator, wants to model a revenue-share or merchant-cash-advance deal, project cash flow and repayment, compute a Cash-Flow Payout Multiple, effective annualized merchant cost, or compare/underwrite multiple financing scenarios. Pure deterministic math, no external calls, no real trading/payment side effects. Scenario create/edit/delete and the underwriting decision are direct writes made by the analyst, not a review/approval queue.
日本語の概要は準備中です。原文の説明を表示しています。
Builds multi-touch pipeline attribution models and generates stakeholder-ready narratives from campaign performance data. Use when analyzing channel contribution to pipeline, preparing monthly/quarterly revenue reports for leadership, diagnosing pipeline misses, modeling budget reallocation scenarios, or translating raw attribution data into board-deck language. Designed for B2B SaaS demand gen teams that report on pipeline and revenue, not leads or MQLs.
日本語の概要は準備中です。原文の説明を表示しています。
Use when the user asks about speakers, talks, schedules, or CFP dates for any Devoxx or VoxxedDays conference. Covers: speaker bios/socials, talk topics/tracks/levels, daily program or room agenda, most popular talks, upcoming or past events, and CFP open/close dates. Queries the public CFP API at [event-slug].cfp.dev and the devoxxians.com event registry. Example triggers: who speaks about Kubernetes at Devoxx UK, what is on Wednesday in Room 8, find AI talks at Voxxed Zurich, when does the CFP open for Devoxx Belgium.
日本語の概要は準備中です。原文の説明を表示しています。
Playwright e2e testing: production-level scenarios, screenshots, responsive scroll. Use when implementing, reviewing or testing playwright e2e testing for React, Vite, Next.js or Perfect_AI projects.
日本語の概要は準備中です。原文の説明を表示しています。
Detects and analyzes malicious behavior in mobile applications through behavioral analysis, permission abuse detection, network traffic monitoring, and dynamic instrumentation. Use when analyzing suspicious mobile applications for data exfiltration, command-and-control communication, credential stealing, SMS interception, or other malware indicators. Activates for requests involving mobile malware analysis, app behavior monitoring, trojan detection, or suspicious app investigation.
日本語の概要は準備中です。原文の説明を表示しています。
Builds SOC performance metrics and KPI tracking dashboards measuring Mean Time to Detect (MTTD), Mean Time to Respond (MTTR), alert quality ratios, analyst productivity, and detection coverage using SIEM data. Use when SOC leadership needs operational visibility, continuous improvement tracking, or executive-level reporting on security operations effectiveness.
日本語の概要は準備中です。原文の説明を表示しています。
GitHub Actions security review for workflow exploitation vulnerabilities. Use when asked to "review GitHub Actions", "audit workflows", "check CI security", "GHA security", "workflow security review", or review .github/workflows/ for pwn requests, expression injection, credential theft, and supply chain attacks. Exploitation-focused with concrete PoC scenarios.
日本語の概要は準備中です。原文の説明を表示しています。
Help users debug PostHog Error Tracking stack-trace symbolication for any supported platform — JavaScript/TypeScript web, React Native (Hermes), Android (Proguard / R8), or iOS / macOS (dSYM). The PostHog symbol-set lookup flow is universal across platforms; build-tool and artifact details live in per-platform references (JavaScript is fleshed out, others come as we encounter them). Use when stack frames stay minified or obfuscated after symbols are uploaded, PostHog symbol sets show last_used but frames are not readable, chunk IDs or dSYM UUIDs do not match, "Token not found" appears, uploaded source maps / dSYMs / Proguard mappings look empty, or bundler / symbol-upload configuration needs troubleshooting.
日本語の概要は準備中です。原文の説明を表示しています。
Diagnoses why a session recording is missing or was not captured. Use when a user asks why a session has no replay, why recordings aren't appearing, or wants to troubleshoot session replay capture issues for a specific session ID or across their project. Covers SDK diagnostic signals, project settings, sampling, triggers, ad blockers, and quota/billing scenarios.
日本語の概要は準備中です。原文の説明を表示しています。
Configures the rollout shape of a PostHog experiment — the variant split (50/50, 80/20, A/B/C ratios), the overall rollout percentage that gates how many users enter the experiment, and the disambiguation when a percentage like "roll out to 25%" could mean either. Use when the user mentions a rollout percentage, variant split, or traffic distribution; gives a ratio like 60/40, 70/30, or 80/20; asks "who sees the test variant?"; wants to increase, decrease, or change the rollout or split on a draft or running experiment; weighs equal vs uneven splits; or proposes a mid-experiment split change (often an anti-pattern that needs reset or end-and-restart).
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.
日本語の概要は準備中です。原文の説明を表示しています。
Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.
日本語の概要は準備中です。原文の説明を表示しています。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
日本語の概要は準備中です。原文の説明を表示しています。